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ABSTRAK 
MASA KEMANDIRIAN DAN FAKTOR-FAKTOR PROGNOSTIK PESAKIT 
AIDS DI KELANTAN: 2010-2014 
Latar belakang: Kematian berkaitan AIDS ini masih menjadi kebimbangan di seluruh 
dunia serta di negeri Kelantan. Walaubagaimanapun masa kemandirian median dan 
faktor-faktor kebarangkalian yang menyumbangkan kepada risiko kematian di 
kalangan pesakit AIDS di Kelantan adalah tidak diketahui. 
Objektif: Untuk menentukan keseluruhan masa kemandirian median dan faktor-faktor 
kebarangkalian kematian dalam kalangan pesakit AIDS di dalam populasi Kelantan 
dari tahun 2010 hingga 2014. 
Kaedah: Satu kajian kohort retrospektif telah dijalankan pada Januari 2018 
menggunakan data sekunder diperolehi daripada Pendaftaran AIDS Nasional bagi 
tempoh 1 Januari 2010 hingga 31 Disember 2014 dan susulan sehingga 31hb Mac 
2015. Sebanyak 1073 data yang lengkap telah dipilih untuk analisa deskriptif dan 
analisa kemandirian. Analisa menggunakan kaedah Kaplan - Meier dan model Cox's 
regresi bahaya berkadar dengan anggaran bahaya nisbah dan 95% selang keyakinan 
digunakan. 
Keputusan: Purata umur (SD) ketika diagnosis adalah 37.08(7.37) tahun. Sebahagian 
besar kes kebanyakannya adalah lelaki (87.0%), Melayu (87.5%), bujang (62.3%), 
menganggur (38.0%), status pendidikan menengah (78.1%) dan kes tanpa jangkitan 
HIV-TB (62.8%). Anggaran 53% kematian pesakit semasa waktu susulan. Masa 
median kemandirian keseluruhan ialah 11 bulan. Kebarangkalian kelangsungan hidup 
dalam tempoh 1 tahun, 2 tahun dan 5 tahun masing-masing adalah 49.1%, 47.8% dan 
xix 
 
46.7%.  Multivariat Cox regresi menunjukkan bahawa factor-faktor kebarangkalian 
kematian adalah berdasarkan umur 30-49 tahun (Adj. HR 1.57; 95% CI: 1.14, 2.16; p 
= 0.006), lelaki (Adj. HR 1.39; 95% CI: 1.07, 1.79; p = 0.012), menganggur (Adj. HR 
1.40; 95% CI: 1.12, 1.75; p = 0.003) dan mempunyai jangkitan HIV-TB (Adj. HR 
1.78; 95% CI: 1.37, 2.31; p < 0.001). 
Kesimpulan: Keseluruhan masa kemandirian median dalam kalangan pesakit AIDS di 
Kelantan adalah masih rendah. Untuk meningkatkan kadar kemandirian hidup di 
kalangan pesakit-pesakit AIDS, segala usaha perlu dibuat untuk memastikan saringan 
awal, diagnosis awal, intervensi awal dan pengurusan yang komprehensif melibatkan 
permulaan rawatan HAART dengan segera dalam merawat pesakit HIV/AIDS 
sebelum berlakunya kematian berkaitan AIDS. 
KATA KUNCI: 
HIV/AIDS, keseluruhan masa kemandirian median, kadar kemandirian, faktor-faktor 
prognostik 
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ABSTRACT 
SURVIVAL TIME AND PROGNOSTIC FACTORS OF AIDS PATIENTS IN 
KELANTAN: 2010-2014 
Background: The AIDS death is still a worldwide concern as well as in Kelantan. 
However, the median survival time and predictor factors that contributing to risk of 
death among AIDS patients in Kelantan were unknown. 
Objectives: To determine the overall median survival time and survival rate of AIDS 
patients and predictors factors of death in Kelantan population from 2010 to 2014. 
Methodology: A retrospective cohort study was conducted in January 2018 using 
secondary data obtained from National AIDS Registry for the period of 1st January 
2010 to 31st December 2014 and followed-up until 31st Mac 2015. A complete 1073 
data was selected for descriptive analysis and survival analysis. Kaplan- Meier survival 
analysis and Cox’s proportional hazard regression model with estimates of hazard ratio 
and 95% confidence interval were used. 
Result: The mean (SD) age was 37.08 (7.37). The patients were predominantly males 
(87.0%), Malays (87.5%), single (62.3%), unemployed (38.0%), with background of 
secondary education (78.1%) and cases without HIV-TB co-infection (62.8%). 
Approximately 53% of the patients death during follow-up. The overall median 
survival time was 11 months. The probability of survival in 1-year, 2-year and 5-year 
were 49.1%, 47.8%, and 46.7% respectively. Multivariate Cox regression showed that 
significant prognostic factors were age 30-49 years (Adj. HR 1.57; 95% CI: 1.14, 2.16; 
p=0.006), male (Adj. HR 1.39; 95% CI: 1.07, 1.79; p=0.012), unemployed (Adj. HR 
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1.40; 95% CI: 1.12, 1.75; p=0.003) and HIV-TB co-infection (Adj. HR 1.78; 95% CI: 
1.37, 2.31; p<0.001). 
Conclusion: The overall median survival time among AIDS patients in Kelantan was 
still low. To increase the survival among AIDS patients, every effort need to be made 
to ensure early screening, early diagnosis, early intervention and comprehensive 
management involving initiating HAART treatment as soon as possible in treating 
HIV/AIDS patients before they progress to AIDS-related death.   
KEYWORDS: 
HIV/AIDS, overall median survival time, survival rate, prognostic factors    
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CHAPTER 1 
INTRODUCTION 
1.1 HIV/AIDS  
Globally, human immunodeficiency virus (HIV) still being address as a threat to the 
public health problem (WHO,2017). However, the Acquired immunodeficiency 
syndrome (AIDS) is no longer public health concern due to the successfully and 
advance of modern antiretroviral therapy (ART) that effectively suppressing HIV 
within a person’s body. Finding found that patient with HIV can live longer with any 
manifestation of AIDS (Cahill and Valadéz, 2013). The AIDS is a term which applies 
to the most advanced stages of HIV infection that can damage body’s immune system 
(WHO,2017).   
AIDS as a result of profound immunosuppression causing the HIV-infected 
individuals vulnerable to opportunistic infections, secondary neoplasms and 
neurologic manifestation. As in case definition for infectious diseases in Malaysia, an 
adult (age more than 12 years old) is considered to have AIDS if tested positive for 
HIV antibody, and one or more of the following is present: (1)10% body weight loss 
or cachexia, with diarrhoea or fever, or both,   intermittent or constant, for at least 1 
month, not known to be due to a condition unrelated to HIV infection; (2) Cryptococcal 
meningitis; (3) Pulmonary or extra-pulmonary tuberculosis; (4) Kaposi sarcoma; (5) 
Neurological impairment that is sufficient to prevent independent daily activities not 
known to be due to a condition unrelated to HIV infection (for example, trauma or 
cerebrovascular accident); (6) Candidiasis of the oesophagus (which may 
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presumptively be diagnosed based on the presence of oral candidiasis accompanied by 
dysphagia); (7) Clinically diagnosed life-threatening or recurrent episodes of 
pneumonia, with or without etiological confirmation; and (8) Invasive cervical cancer 
(MOH, 2017).  
1.1.1 The natural history of HIV                                                               
The natural history of untreated HIV varies widely. The treatment planning and 
preventive strategies are depending on the long term development of non-progression 
of HIV and viral control (Sabin and Lundgren, 2013). A better understanding of the 
epidemiological triad that involving the host, agent and environmental factor is crucial 
in providing the prevention and control of the disease spread.   
The dynamic interaction of the agent-host can be explained through the 
progression of disease. It’s started from the susceptible infected of the host with the 
agent typically HIV-1. The acute phase or so called primary infection of adults HIV 
infection occur after 3 to 6 weeks of infection followed by chronic phase. Most of the 
HIV patient are asymptomatic with a CD4+ count of 350-800 cells/mm3 in chronic 
phase. The primary infection may symptomatic and or asymptomatic which usually 
correlate with faster progression. The antibodies usually appear two to four weeks later 
(Lavreys et al., 2002). The self-limited illness that occur in primary infection showing 
the nonspecific symptoms such as fever (80%), malaise (68%), arthralgia (54%), 
maculopapular rash (51%), myalgia, oral ulcers and pharyngitis whereas neurological 
complications such as Guillaine Barre´syndrome and Bell’s palsy occasionally occur. 
Most of the symptoms resolved after 7-10 days. Some of the patient develop more 
severe symptoms that usually associated with opportunistic infection such as 
Pneumocystis jirovecii pneumonia (PCP) or oesophageal candidiasis with the CD4+ 
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count below 200 cells/mm3 (Lewthwaite & Wilkins, 2009). This phase recognized by 
detection of lower CD4+ T cells but the virus production and viremia was at higher 
level. When the dissemination of virus occurs, there was a sharply decrease of the 
CD4+ cell count in the peripheral blood. These is where the prolonged period of 
clinical latency occurs. 
In the stage of clinical latency period, the individual doesn’t show any 
symptoms but the HIV replication, CD4 depletion and viral evolution continues and 
lasting for several years. The United Kingdom (UK) study done by Mandalia et al. 
shows that asymptomatic individual can live up to more than 7 years presumably 
because of stable CD4+ cell counts. Patients also can have persistent lymphadenopathy 
and many patients have minor opportunistic infections such as oral thrush (candida) or 
herpes zoster (Lewthwaite & Wilkins, 2009). The crisis phase begins when there are 
clinical features of persistent lymphadenopathy with significant constitutional 
symptoms such as fever, rash and fatigue. It shows the decompensation of immune 
system with increase production of viral replication. 
The crisis phase is the final phase that characterized by catastrophic breakdown 
of host defences, a marked increase in viremia and clinical disease. Patients may 
present with fever of more than one month’s duration, fatigue, weight loss and 
diarrhoea with the CD4+ cell count reduced below 500 cell/mm3. Patients may prone 
to serious opportunistic infections and develop secondary neoplasms and/or neurologic 
manifestations. This is so-called AIDS defining condition (Figure 1.1). The Centre of 
Disease Control (CDC) guidelines define AIDS as any HIV-infected individual with 
CD4+ cell counts less than or equal to 200 cell/mm3. The total years of survival from 
the HIV infected person to the diagnosis of AIDS is approximately 8-10 years (Sabin 
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& Lundgren, 2013). A study reported that the survival of AIDS patient to death without 
any intervention is approximately within two years (Poorolajal et al., 2016). 
 
Figure 1.1: The typical clinical course of HIV disease 
1.1.2 Risk Factor 
The risk factors of HIV are depending on the types of exposure and behaviour. 
The infectious agent of HIV involve transmission from person-to-person through 
unprotected penile-vaginal or penile-anal intercourse; the use of HIV-contaminated 
injecting and skin-piercing equipment, including sharing of needles and syringes by 
people who inject drugs; vertical transmission from mother to infant during pregnancy, 
delivery or breastfeeding and transfusion of infected blood or its components. The 
heterosexual HIV infection is the main contributor of mode of transmission in Sub-
Saharan Africa and South-East Asia Region that mostly affected the young women 
(CDC, 2015).  
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The updates information of Ministry of Health Malaysia “Ending AIDS in 
Malaysia” shows the changing pattern of HIV transmission from the people who inject 
drugs (PWID) to the sexually transmitted HIV infection mostly men having sex with 
men (MSM). This evidence supported by the latest Integrated biological and 
behavioural surveillance survey (IBBS) in 2014. The IBBS is done mainly to establish 
information that contributes towards developing an evidence- informed response to 
HIV and AIDS that was initially conducted in 2009. Total of three round of IBBS 
survey was done. At initial part the IBBS survey was concentrate for three key 
population which is PWID, female sex worker (FSW) and transgender (TG) then for 
second and third round focusing on wider group which included the MSM people. This 
survey was successfully being implemented countrywide in 2012 and 2014.  
The IBBS done in 2014 reported that the HIV prevalence among PWID 
declining from 22.1% to 16.3% in 2009 and 2014 respectively. Whereas, the HIV 
prevalence among MSM was increasing from 3.9% in 2009 to 8.9% in 2014. The other 
groups that contribute to the increase of HIV transmission through sexual are FSW 
and TG which showing the percentage of 10.5% in 2009 and 7.3% in 2014, later is 
9.3% in 2009 and 5.6% in 2014 respectively (NSPEA, 2015). However, in IBBS 2014 
even though nationally showed slowly declining HIV transmission through PWID but 
Kelantan is still dominated by PWID with HIV prevalence 44.7% followed by 
Terengganu (30.0%), Johor (27.1%) and Kuala Lumpur (21.3%). Penang (1.6%) and 
Melaka (1.7%) were among the lowest HIV prevalence in PWID. Kuala Lumpur 
(17.1%) and Pahang (14.5%) is the state mostly predominant by sexually transmitted 
of HIV infection mainly FSW and lowest in Perak (0.6%). In 2014, the prevalence 
among MSM and TG were highest in Kuala Lumpur which 22.0% and 10.6% 
respectively (NSPEA, 2015). 
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1.2 HIV/AIDS incidence, mortality and survival 
In the past 30 years there are a lot of achievement and programmes being done to 
combat HIV/AIDS but yet it’s still remains a major threat to the public health (GBD, 
2015). However, HIV/AIDS is no longer among the world’s top 10 causes of death 
(WHO, 2017). AIDS mortality has been declining at a steady pace, from peak of 1.9 
million in 2005 to 1.0 million in 2016 about 48% declining of the AIDS-related death 
(UNAIDS, 2017). There is no cure and vaccine yet for this moment but the global 
response is to reduce the burden of the disease to those infected and to prevent further 
infections spread. 
 Globally, an estimated 36.7 million people living with the HIV infection at the 
end of 2016 with the HIV prevalence 0.8% among adults (UNAIDS, 2017). In 2016, 
reported 1.8 million newly infected with HIV (WHO, 2017). From the start of 
epidemic till now an estimated 78 million people suffering from HIV infection and 
from that 35 million people have died because of AIDS-related illness. New HIV 
infection has declined by 50% between 2000 and 2015 while the number of HIV/AIDS 
related deaths stabilized during the same period. About 16% of reduction in number 
of AIDS death across the global population since 2010 (UNAIDS, 2017). The most 
affected countries with the HIV infection was the African region with the estimated 
number of people living with HIV was about 25.6 million in 2016 (WHO, 2017). 
Survival probabilities of progression from AIDS onset to AIDS-related death between 
patient with Highly Active Antiretroviral Therapy (HAART) and without HAART 
have change. Reported from meta-analysis research of 57 studies, an estimated the 6-
year survival those from AIDS onset to AIDS-related death in patient receive HAART 
and who did not were 78% and 18% respectively (Poorolajal et al., 2016). 
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In Western Pacific region, the estimated number of people living with HIV 
(PLHIV) was 1.28 million in 2010 and the number increase to 1.48 million in 2016. 
However, the prevalence still low, 0.1% which mask the high HIV infection among 
key affected population. The new infection of HIV also decreases from 120,000 in 
2000 to 97,000 in 2016. The AIDS-related death reported have been declining over the 
past year from 65,000 in 2005 to 39,000 in 2016. China is the main country that 
contributed to the higher new HIV infection which was 63.02% out of 37 countries in 
Western Pacific Region. Reported data from year 2000 to 2015 for Western Pacific the 
increased use of antiretroviral therapy (ART) corresponds with the decrease in AIDS-
related deaths. As ART use increased up to 50% in 2015, AIDS-related deaths began 
to slow and decrease to 40,000 cases ("Global, regional, and national incidence, 
prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a 
systematic analysis for the Global Burden of Disease Study 2015," 2016).      
The first reported case of AIDS in Malaysia was in 1986 (UNAIDS, 2016). 
Since then, the cumulative number of AIDS-related death from year 1989 to 2016 were 
18,827 with people diagnosis of AIDS were 23,717 (GARPR, 2016). In 2016, almost 
50% reduction of the new HIV infection as compared to year 2000 from 12,000 to 
5700 cases. The AIDS-related death was 7000 in 2016. Same as other countries the 
survival of AIDS patients in Malaysia was markedly improving after ART treatment 
or HAART was introduced in 1996 (Mat Shah et al., 2012). Since then, the natural 
history of HIV/AIDS as well as morbidity and mortality pattern have changed (May 
and Ingel (2011). The HIV-infected person experiencing immune reconstitution and 
prolonged survival as result of HAART. New antiretroviral with lesser side-effect 
facilitated adherence to treatment and contributed to increasing life expectancy 
(Nakagawa et al., 2013). In Malaysia, survival analysis research done by Lubis et al. 
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(2013) reported that the data from 845 HIV-infected patients aged ≥20 years on ART 
in a large teaching hospital in Malaysia from 1989 to 2009 was survived up to 72.7% 
if the viral load less or equal than 50 copies/ml. The mean survival time was 130.9 
(95% CI: 123.4, 138.3) month. The triple drug ART used to treat HIV patients and to 
lower viral load to ≤50 copies/ml was the significant modifiable predictors of death in 
Malaysian HIV patients. 
Kelantan is among the five states that account for almost two thirds (62%) of 
all people living with HIV (PLHIV) in Malaysia. The epidemic snapshot Kelantan 
2016 database showed that the cumulative number of AIDS cases from year 2001 to 
2016 was 2,255 cases and the AIDS-related death was 174 cases in 2016. There is no 
survival analysis done yet in Kelantan up to this date. 
1.3 Malaysian AIDS Surveillance and National AIDS Registry 
The AIDS surveillance system in all states in Malaysia is active and comprehensive. 
It involves both public and private medical care providers including hospitals, health 
clinic, physicians, general practitioners and laboratories. All cases of HIV, AIDS and 
AIDS-related death diagnosed by registered medical practitioners are mandatorily 
notifiable as stipulated by Prevention and Disease Control Act 1988. 
This surveillance system aims to better characterize the newly diagnosed HIV 
population and to facilitate the public health follow up. The sources of notification 
include health facilities, routine HIV testing among people who inject drugs in drug 
rehabilitation centres and prisons, tuberculosis (TB) and sexually transmitted diseases 
(STD) patients, pregnant women attending antenatal clinics and blood donors. The 
system was upgraded to web-based notification in 2001. 
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The Ministry of Health established the National AIDS Registry (NAR) in 2009. 
It is intended to replace the existing surveillance system designed to function as a 
streamlined and effective national HIV programme monitoring mechanism that able 
to capture detailed disaggregated data continuously and systematically. The registry 
captures data on each HIV patient relating to their socioeconomic background, risk 
factor, date of confirmation, contact information, AIDS-related symptoms etc. The 
data was entered since 2000 taken from manual registration HIV/AIDS report. The 
data includes all notifiable HIV, AIDS and AIDS death by government and private 
hospital according to every state but only the HIV/STD/Hep C Unit of respective state 
and administrator, HIV/STI Section of Disease Control Division, Ministry of Health 
Malaysia able to access the data with the ID number and password to enter the system. 
Besides the passive notification from government hospitals, clinic and private 
setting, the HIV/STI/Hep C Unit also conducted an active case detection by doing the 
outreach program screening cooperated with non-governmental organization (NGO). 
The programmes were through testing and screening programmes include routine HIV 
screening of all donated blood, blood products and organs, opt-out antenatal screening, 
routine testing of inmates in drug rehabilitation centres and prisons, testing of TB and 
STI patients, clients of harm reduction programme, contacts of HIV infected persons, 
and voluntary premarital testing. The notification form received from various sources 
mentioned will be verified by the Epidemiologist or Public Health Specialist of 
HIV/STI/Hep C Unit at every district before the respective district registered to the 
National AIDS Registry and further analyses by the HIV/STD/Hep C Unit at every 
respective state. 
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1.4 Problem statement 
There were studies done with regards to survival of HIV/AIDS patients and looking 
the prognostic factors of survival worldwide. Reports of improved survival among 
persons living with AIDS were well documented in most of the literature in the late 
1990s especially after the ART initiation. 
Recently studies from Western countries showed improvement in survival 
among the AIDS patients. The striking pattern of improving the prevalence and 
incidence worldwide with the increase of the ART coverage highlighted that the 
changes in the patient survival ("Life expectancy of individuals on combination 
antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort 
studies," 2008).  
In Malaysia, HIV epidemics still concentrated with the key affected population 
(sex workers, men having sex with men, transgender persons and people who use 
drug). Hence, identification of current survival status and the factors influencing the 
survival among AIDS patient was crucial since no such study has been carried out in 
Malaysia. 
Locally, there was no population-based study done yet to evaluate the survival 
and prognostic factors of AIDS patient. Even though the prognostic factor of death 
research finding from Western Countries were numerous, but it may not readily be 
adapted to Malaysia and Kelantan per say as the outcome of AIDS depends on a 
multitude of factors ranging from sociodemographic factors and clinical 
characteristics. It is therefore critical to conduct this survival time analysis among 
AIDS patients to meet the need for region-wide information. 
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1.5 Rationale of study 
The impact of HIV response should be assessed by monitoring changes in AIDS-
related death over time. By identification of prognostic factors of death in AIDS patient 
will help to guide HIV/AIDS prevention, care and treatment programmes in Kelantan 
as well. It can guide clinician for prompt treatment in order to reach the target of 
National Strategic Plan of Ending AIDS 2016-2030 (NSPEA) which are 90% of key 
affected population tested for HIV and know their result, 90% of PLHIV receive ART 
and 90% of people on ART achieve viral suppression.  
So, with the detail of survival time among AIDS patients can help the clinician 
to use the local data to convince patient about overall prognosis of AIDS survival. It’s 
also can be used as a guidance in planning further management. Therefore, we will be 
able to improve the survival time among the AIDS patient in Kelantan and hence alert 
the health care professional to diagnoses AIDS as early as possible. Moreover, the 
research done in Malaysia only focusing on the survival with regards of treatment 
modalities. In this study, the broader factor can be included to see the survival of the 
AIDS patients either increase or decrease with regards of the other modalities such as 
sociodemographic factors and HIV-TB co-infection as these variables are available 
and complete in our secondary data in National AIDS Registry. 
Meanwhile, the determination of survival time and prognostic factors of death 
among AIDS patient information will serve several purposes: 1) increase knowledge 
on the medical and public health level determinants of survival after AIDS diagnosis; 
2) to enhance planning and allocations of resources for HIV/AIDS services; and 3) 
provide the detection of changes that may help in the success of the services and the 
area of gaps for improvement of the survival times among AIDS patients. There was 
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still lack of research done on survival among AIDS patients in Malaysia and no study 
done yet at Kelantan state. So, the primary aim of this study was to determine the 
survival time and survival rate as well as the prognostic factors of AIDS patients in 
Kelantan.  
1.6 Research questions 
I. What is the median survival time of AIDS patients in Kelantan? 
II. What is the survival rate of AIDS patients in Kelantan? 
III. What are the prognostic factors of AIDS patients in Kelantan? 
1.7 Objectives 
1.7.1 General objective 
To determine the overall median survival time and prognostic factors of AIDS patient 
in Kelantan from 2010-2014. 
1.7.2 Specific objectives 
1. To determine median survival time of AIDS patients in Kelantan diagnosed 
between 2010-2014. 
2. To determine the survival rate of AIDS patients in Kelantan 
3. To determine the prognostic factors (sociodemographic and HIV-TB co-
infection) of death among AIDS patients in Kelantan. 
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1.8 Hypothesis 
1.8.1 Alternative hypothesis 
There are an association between prognostic factors (sociodemographic and HIV-TB 
co-infection) with the death among AIDS patients in Kelantan. 
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CHAPTER 2 
LITERATURE REVIEW 
All the literature searches pertaining to survival, HIV/AIDS and the prognostic factors 
were widely done by using search engines such as PubMed, Science Direct, Springer 
Link and Ebcohost. Various searching strategy was applied such as combination of 
terms with the use of Boolean operators (AND, OR, NOT). The entire literature search 
published from 2000-2017 were included. Key words used were HIV/AIDS, median 
survival time, survival rate and predictors of death. 
2.1 The Infectious Agent: Human Immunodeficiency virus  
The causative agent for AIDS is Human immunodeficiency virus (HIV). The HIV is a 
retrovirus that contains only RNA. The HIV is a human retrovirus belonging to the 
lentivirus family including feline immunodeficiency virus, simian immunodeficiency 
virus, visna virus of sheep, and the equine infectious anaemia virus which has two 
types known as HIV-1 and HIV-2. The HIV-1 is the most common types of infectious 
agent that contribute to worldwide AIDS epidemic. The later type is much less 
common and less virulent, but eventually produces clinical findings similar to HIV-1 
(Sharp & Hahn, 2011). The HIV-1 type itself has two broader groups, designated M 
(major) and O (outlier). The most common form of group M are further divided into 
subtypes A through J which have differing geographic distributions but all produce 
AIDS similarly. Subtypes B most common form in Western Europe and United States 
and E most common form in Thailand. The different subtypes also exhibit different in 
mode of transmission. For example, the subtype E is spread predominantly by 
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heterosexual contact (male-to-female), presumably because of its ability to infect 
vaginal sub epithelial dendritic cells. Compare to the subtype of B, the virus best 
transmitted by introduction of infected monocytes and lymphocytes due to poorly 
grows of the subtypes in the dendritic cells (Robbins, 2003). 
Emergence of HIV infection started since 1980s originated from a man in 
Kinshasa, in the Democratic Republic of Congo collected from his blood around 1959. 
In the beginning, mostly believes that the source of HIV is come from ‘homosexual’. 
However, research found that HIV is related to Simian Immunodeficiency Virus (SIV) 
which is originated from non-human primate progenitor and not because of long 
misguided associations of it being a “gay flu,” disease of immigrants or commonly 
called homosexual and intravenous drug users. The SIV having similar way with HIV 
attack the immune system but happen to the monkeys and apes (Sharp & Hahn, 2011). 
The researcher reported that the type HIV-1 is related to the strain of SIV found in 
chimpanzees and strain of SIV in sooty mangabeys closely related to HIV-2. The 
accepted theory behind the changing of SIV to HIV was started since 1999, where the 
researcher found that the virus was transferred to human from chimp when their blood 
getting into as a result of hunted chimp killed and eaten by them. The genetic evidence 
show the virus evolved and adapted in the new host (human). SIV became 
transmissible to humans and developed into HIV (Worobey et al., 2010). 
2.1.1 Structure of HIV 
The structure of mature HIV is a spherical shape of virion that consists of a bar-shaped 
electron dense core containing the viral genome; two short strands of ribonucleic acid 
(RNA) each 9200 nucleotide bases long, encased with the enzymes reverse 
transcriptase, protease, ribonuclease, and integrase within an outer lipid envelope 
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derived from a host cell (Figure 2.1). The outer coat of virus consists of two layers of 
lipids which is the outer ‘spike’ consist of different protein that embedded in the viral 
envelope called glycoprotein and the transmembrane. The transmembrane is needed 
in the process of cell fusion whereas the glycoprotein is crucial when the virus has to 
attach to the host cell to start the replication process.  
The basic components of HIV consist of three important and major genes 
called: envelope glycoprotein (env), group specific antigen (gag), and pol (reverse 
transcriptase, protease and integrase) which code for various viral proteins. The env 
genes form an envelope precursor protein gp160 which undergoes proteolytic cleavage 
to the outer envelope glycoprotein gp120. The gp120 responsible for tropism to CD4+ 
receptors. The transmembrane glycoprotein gp41 combined with glycoprotein gp120 
to the target cell's membrane. The gag gene develops the proteins of the matrix p17, 
the "core" capsid p24, and the nucleocapsid p7. The pol gene synthesis the important 
enzymes such as reverse transcriptase p51 and p66, integrase p32, and protease p11. 
The antibody recognizes the p24 that used to diagnose HIV infection in blood 
screening (Fajardo-Ortiz et al., 2017). Other than three standard retroviral genes, HIV 
contains other several genes named tat, rev, vif, nef, vpr, and vpu which regulate the 
synthesis and assembly of infectious viral particles. The replication of the virus that 
can produce up to 1000-fold increase in viral genes transcription done by the product 
of tat (transactivator) gene. The activation intracellular kinase activity mainly T-cell 
activation, viral replication and viral infectivity is particularly done by the nef protein 
and also needed for progression of HIV infection in vivo (Figure 2.2). 
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Figure 2.1: Virus HIV structure 
 
 
Figure 2.2: The HIV genome 
2.1.2 Pathogenesis of HIV 
The immune-pathogenesis of HIV disease are particularly causing the 
immunosuppression that primarily affecting cell-mediated immunity. This result from 
the infection and subsequently loss of CD4+ T cells as well as impairments in the 
function of surviving helper T cells. The coreceptor of CD4 receptor also known as 
chemokine responsible for HIV infection. However, binding to CD4 is not sufficient 
for infection without the HIV envelope gp120 also bind to the coreceptors to facilitate 
18 
 
cell entry. Chemokines are cell surface fusion-mediating molecules. Such coreceptors 
include CXCR4 and CCR5. Their presence on cells can aid binding of the HIV 
envelope glycoprotein gp120 act as infection promoter. Initial binding of HIV to the 
CD4 receptor is mediated by conformational changes in the gp120 subunit, but such 
conformational changes are not sufficient of fusion. The fusion of HIV happens when 
the conformational change of gp41 subunit produce by chemokine receptors. The 
differences in chemokine coreceptors that are present on a cell also explains how 
different strains of HIV may infect cells selectively. The process of infection to 
lymphocytes was done by T-tropic strains which selectively interact with CXCR4 
chemokine corereceptor. The M-tropic strains of HIV interact with the CCR5 
chemokine coreceptor to infect macrophages. Dual tropic HIV stains have been 
identified. In some cases, when there was a resistance to HIV infection probably due 
to CCR5 mutation. The capability of this routes produce HIV resistance may increase 
the ability of virus to infect cells easier.  
Most of the patient develop the stage of clinical AIDS when the CD4 
lymphocyte count drops below 200/microliter. It has been determined that 
approximately 100 billion new viral particles are produced every day and one to two 
billion CD4+ T cells die each day. The loss of CD4+ cells can occur by both increased 
destruction and reduced production (Robbin, 2003). 
2.1.3 Transmission 
The most commonly mode of transmission of HIV infection is by sexual 
contact, either homosexually or heterosexually but again about 85% type HIV-1 all are 
coming from heterosexual transmission (Simon et al., 2006). Solely change the 
perception that HIV transmission is a disease of homosexual. Same reported by Center 
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for Disease Control, United State (US) in 1983 (Greene, 2007). The virus enters to the 
body through the lining of the vagina, vulva, penis, rectum, or mouth during sexual 
contact. The other mode of transmission is through contact with infected blood or 
blood products, or tissues from transfusion and transplants. The sharing needle or 
syringes during intravenous drug use are other blood-borne routes. Mother-to-child 
transmission of HIV is the spread of HIV infection from infected mother to child 
during pregnancy, childbirth or breastfeeding. According to the WHO the transmission 
rate mother-to-child transmission is range from 15% to 45% without any intervention. 
The systemic review study on HIV modes of transmission found that 13 out of 
29 countries that have been reported shows the low-risk group are more vulnerable to 
HIV transmission (26-63%) and female sex workers (FSW) still remain low (median 
1.3%) and the people with intravenous drug user (PWID) even they are the largest 
contributor to HIV transmission in early-phase of endemic reported to have low overall 
HIV prevalence. The sexual contact through men who have sex with men show 
increasing size in population and the annual fraction of new HIV infections reported 
varies across region (range 0.1 to 82%) (Shubber et al., 2014).    
2.1.4 Progression to AIDS 
The progression of HIV to AIDS presentation is still debatable. The asymptomatic 
HIV infection to develop AIDS varies from patient to patient and the determinants are 
not clearly stated. The identification of AIDS started in 1981 when there are young 
gay men in US sick and on the point of death after suffering from an opportunistic 
infection. The speculation stated that AIDS was originated from Haiti as appearance 
of AIDS in Haiti. Late 1982, epidemiologic evidence reported that AIDS transmitted 
by bodily fluids and contaminated blood. A true cause of AIDS found after 
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immunological intervention show the level of CD4 T cell rapidly decrease to the level 
of 200 cell/mm3 make them prone to opportunistic infection and various malignancy 
(Greene, 2007). The previous study reported that the reduced number of T-helper 
lymphocytes, increase T-suppressor lymphocytes and reduced amount of serum 
antibody to HIV are the most likely determinants of progression of AIDS (Desalu, 
2002).   
2.2 HIV/AIDS burden 
The incidence and mortality of HIV/AIDS as public health concern is mostly common 
indicator for the disease burden. The HIV/AIDS is one of the disease attributable to 
the total disability mainly in Southern Sub-Saharan African countries (GBD, 2016). 
The changing pattern HIV/AIDS burden reported based on the global burden of disease 
study 2015 shows the global HIV incidence peak in 1997, 3.3 million new infections 
and declining fast between 1997 and 2005. Since then the incidence was steadily 
constant about 2.6 million per year. However, in 2015 the number of people living 
with HIV/AIDS increasing and reached to 38.8 million (GBD, 2016). 
 Sub-Saharan Africa with only small population but yet a largest contributor to 
global burden of HIV infection (71%). The new infection still high even reported the 
declining of the trends from 2.2 million in 2005 to 1.5 million in 2013 (Kharsany & 
Karim, 2016a). The declining of the incidence was corresponding with the 
antiretroviral therapy (ART) coverage. The evidence is based on study done by Reniers 
et al. (2014) reveal from data of seven members of the Network for Analysing 
Longitudinal Population-based HIV/AIDS data on Africa (ALPHA Network) cover 
populations ranging from 20 000 to 200 000 in size. The study was carried out to see 
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the mortality trend from period of 2000 to 2011 which cover the pre- and post-ART 
era. The mortality rate ratio in early 2000s (pre-ART era) varied between 8.4 to 21.2 
whereas post-ART era ranged from 2.4 to 6.6. 
Malaysia is one of the faster growing HIV epidemics in the East Asia and 
Pacific region, from three cases in 1986 dramatically increase to 91,362 cases of HIV-
infection, 16,352 AIDS cases and 12,943 AIDS-related deaths by end of 2010 
(NSPEA, 2017). Again same as other countries, the introduction of ART in early 1990s 
gives a new dimension on the survival of people living with HIV from death sentences 
toward manageable chronic condition (Huang & Hussein, 2004).  
2.3 Overall median survival time and survival rate of AIDS 
The overall median survival time showed the first observed time at which the 
cumulative survival was 50% or less. In other word its refers to how long the patients 
survive with a disease in general or after a certain factor such as treatment. It is the 
time which can be expressed either in months or years when half the patients are 
expected to be alive. Meaning that the chance of surviving beyond that time is 50%. 
 In Somali Region, Eastern Ethiopia, a retrospective cohort study done by 
Bereket Damtew et al. (2015) analysed the survival patients who started ART between 
December 1, 2007 and December 31, 2011 at Kharamara hospital. Most of the cases 
were female patient 485 (58.4%). Out of total study population, 87 (11.1%) patients 
died during the five-year follow-up period, with majority of deaths 49(56.3%) 
occurring in the first 3 months. This study revealed the median survival time for event 
(death) was 20.7 months. The estimated mortality was 8.4%, 9.8%, 11.3%, 12.7% and 
14.1% at 6, 12, 24, 36 and 48 months respectively.  
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 The study done by Carvour et al. (2015) on the both retrospective cohort data 
from statewide cohort, Lowa for the period of 1982-2008 and a university-based 
validation cohort during the period 1984–2009. This study identifies the survival of 
AIDS-related neurologic disease between male and female for both cohorts were poor. 
The median survival time was 1.13 years for the statewide cohort and 3.04 years for 
the university-based cohort respectively. In the statewide cohort documented that 
median survival time was lower for women (median: 0.78 years, range: 0.00 to 11.38 
years) than for men (median: 1.30 years, range: 0.00 to 19.04 years) through Kaplan- 
Meier analysis. In the university-based cohort, the rate of death was non-significantly 
higher for women than for men (Adj. HR: 1.44, 95% CI: 0.44 to 4.72, n = 171). 
 Further, Marin et al. (2003) in a subsequent sample of 3930 adult AIDS cases 
from 18 cities in seven states representing all regions of Brazil were randomly select 
cases diagnosed in 1995 and 1996 reported dramatic improvement in survival. This 
retrospective cohort study finding was compared with data from a previous national 
study of survival among 2135 adult Brazilian AIDS patients diagnosed in 1982–1989. 
Out of 3930 cases in the original sample, only 2821 AIDS patients studied. Twenty 
percent of them are female (763) with median age of 33 years. The median survival 
for AIDS cases diagnosed in 1995 is 18 months and cases diagnosed in 1996 had much 
better survival (median survival: 58months). The median survival time for AIDS 
patients in 1995 and 1996 combined was found to be 36 months. The previous study 
of survival among adult Brazilian AIDS patients in 1982 to 1989 found a median 
survival of 5.1 months.  
Based on survival analysis study by Melo L.S et al. (2008), all the patients 
whose cases were notified over the study period from 1997 to 2004, the probability of 
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survival for the 597 subjects was 82%. This study was carried for those who died over 
eight years of Highly Active Antiretroviral Therapy, at a Referral Center in Northeast 
Brazil. There was a 75% probability of survival for up to 66 months. Among the 597 
patients whose cases were notified as AIDS, 150 (25%) progressed to death. 
Further analysis study of the survival looking in different perspective which is 
the survival of AIDS patient after diagnosis Pneomocystis carinii pneumonia (PCP) in 
United States. The data was obtained from 11 state and local department of United 
State for period of 1992-1998 done by Dworkin et al. (2001). This study was based on 
the data collection began in 1990 (Atlanta, Dallas, Houston, San Antonio, Denver, 
Detroit, Los Angeles, New Orleans, and Seattle), 1991 (New York City), and 1992 
(Bayamon, Puerto Rico) through 1999 showed an improvement in survival with more 
recent year of diagnosis with PCP. Twelve-month survival increased from 40% during 
1992–1993 to 44% during 1994–1995 and then to 63% during 1996–1998. The 
survival in 1-year was increasing in trend from 40% to 68% in 1992 to 1998 
respectively.  
 In Malaysia, the hospital-based study done by Lubis et al. (2013). They studied 
845 HIV- infected patients aged more than 20 years. This cohort study looking 
retrospectively the medical records of patient in large teaching hospital from 1989 to 
2007 and followed up through 2009. From the finding noted were predominantly aged 
between 20 and 39 years (70.4%), were male (78.2%) and were Chinese (67.3%) while 
48.5% were married, 67.5% had at least secondary education, 49.2% were professional 
or non-manual workers. About 74% had CD4<200 cells/μl and 55.5% had viral load 
(VL)≥100,000 copies/ml. This study was focusing on the survival of HIV infected 
patient on antiretroviral therapy. The mean survival time in this cohort was 130.9 (95% 
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CI 123.4, 138.3) months. The cumulative survival was more than 50%, so this study 
unable to calculate the median survival time. The survival rate of HIV infected patients 
on ART were 70.6% and 62.3% in 5-year and 10-year survival.    
Table 2.1: Summary of literature review overall median survival time and survival rate 
of AIDS patient 
Study 
location 
Database (years) 
Overall 
median 
survival 
(months) 
Survival rate Author, Year 
Somali 
Region, 
Eastern 
Ethiopia 
HIV/AIDS patients 
on ART at 
Kharamara hospital: 
PLHIV to death 
(2007-2011) 
20.7 
1-year: 90.2% 
2-year: 88.7% 
3-year:87.3% 
4-year:85.9% 
(Bereket 
Damtew et 
al., 2015) 
Iowa, 
United State 
of America 
Surveillance data 
HIV/AIDS reporting 
system: Neuro-
AIDS to death  
 (Statewide 
cohort:1982-2008 
University-based 
cohort: 1984-2009) 
13 
(Statewide 
cohort) 
36 
(university-
based 
cohort) 
Not stated in 
the study 
(Carvour et 
al., 2015) 
 
 
 
 
 
 
